Published on 19 Jun 2024 on Zacks · via Yahoo Finance
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
Zacks Investment Research has recently initiated coverage of Enzo Biochem, Inc. ENZ, assigning a "Neutral" recommendation to the company's shares. This assessment comes amid a mixed outlook for the company, which has been making notable strides in the life sciences tools market despite industry challenges.
Enzo Biochem, headquartered in Farmingdale, NY, has carved a niche in molecular diagnostics. It provides an extensive array of technical platforms and reagent sets for biomedical research and translational science. The company's Life Science division supports a diverse range of applications, including cell biology and genomics, among others.